Literature DB >> 29161205

Imbalance Between Clinical and Pathologic Staging in the Updated American Joint Commission on Cancer Staging System for Human Papillomavirus-Positive Oropharyngeal Cancer.

Carole Fakhry1, Jose P Zevallos1, David W Eisele1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 29161205     DOI： 10.1200/JCO.2017.75.2063

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  7 in total

Review 1.  Data Set for the Reporting of Carcinomas of the Nasopharynx and Oropharynx: Explanations and Recommendations of the Guidelines From the International Collaboration on Cancer Reporting.

Authors:  James S Lewis; David J Adelstein; Abbas Agaimy; Diane L Carlson; William C Faquin; Tim Helliwell; Jos Hille; Tony Ng; John M Nicholls; Brian O'Sullivan; Lester D R Thompson
Journal:  Arch Pathol Lab Med       Date:  2018-11-30       Impact factor: 5.534

2.  Validation and assessment of discordance of the 8th edition AJCC (American Joint Committee on Cancer) clinical and pathologic staging systems in patients with p16+ oropharyngeal cancer treated with surgery and adjuvant radiation at a single institution.

Authors:  Piyush Gupta; Jocelyn C Migliacci; Ashley Hay; Matthew Rosenthal; Ximena Mimica; Nancy Lee; Richard J Wong; Jatin Shah; Snehal Patel; Ian Ganly
Journal:  Oral Oncol       Date:  2018-06-23       Impact factor: 5.337

Review 3.  Critical Changes in the Staging of Head and Neck Cancer.

Authors:  Christine M Glastonbury
Journal:  Radiol Imaging Cancer       Date:  2020-01-31

4.  From presumed benign neck masses to delayed recognition of human papillomavirus-positive oropharyngeal cancer.

Authors:  Ruth J Davis; Eleni Rettig; Nafi Aygun; Lisa Rooper; Gypsyamber D'Souza; David W Eisele; Carole Fakhry
Journal:  Laryngoscope       Date:  2019-04-05       Impact factor: 3.325

5.  Validation of NRG oncology/RTOG-0129 risk groups for HPV-positive and HPV-negative oropharyngeal squamous cell cancer: Implications for risk-based therapeutic intensity trials.

Authors:  Carole Fakhry; Qiang Zhang; Maura L Gillison; Phuc Felix Nguyen-Tân; David I Rosenthal; Randal S Weber; Louise Lambert; Andy M Trotti; William L Barrett; Wade L Thorstad; Sue S Yom; Stuart J Wong; John A Ridge; Shyam S D Rao; Sharon Spencer; Andre Fortin; David Raben; Jonathan Harris; Quynh-Thu Le
Journal:  Cancer       Date:  2019-03-26       Impact factor: 6.860

Review 6.  Deintensification of treatment for human papillomavirus-related oropharyngeal cancer: Current state and future directions.

Authors:  Elaine O Bigelow; Tanguy Y Seiwert; Carole Fakhry
Journal:  Oral Oncol       Date:  2020-04-02       Impact factor: 5.337

7.  Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI.

Authors:  Aimée R Kreimer; Anil K Chaturvedi; Laia Alemany; Devasena Anantharaman; Freddie Bray; Mary Carrington; John Doorbar; Gypsyamber D'Souza; Carole Fakhry; Robert L Ferris; Maura Gillison; D Neil Hayes; Allan Hildesheim; Shao Hui Huang; Luiz P Kowalski; Krystle A Lang Kuhs; James Lewis; Douglas R Lowy; Hisham Mehanna; Andy Ness; Michael Pawlita; Maisa Pinheiro; John Schiller; Meredith S Shiels; Joseph Tota; Lisa Mirabello; Saman Warnakulasuriya; Tim Waterboer; William Westra; Stephen Chanock; Paul Brennan
Journal:  Oral Oncol       Date:  2020-06-02       Impact factor: 5.337
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.